Sharma, S;
Neale, MH;
Di Nicolantonio, F;
Knight, LA;
Whitehouse, PA;
Mercer, SJ;
Higgins, BR;
... Cree, IA; + view all
(2003)
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
BMC Cancer
, 3
, Article 19. 10.1186/1471-2407-3-19.
![[thumbnail of 1471-2407-3-19.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1471-2407-3-19.pdf Available under License : See the attached licence file. Download (323kB) |
Abstract
BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. METHODS: From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125). RESULTS: The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months). CONCLUSION: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centres
| Type: | Article |
|---|---|
| Title: | Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/1471-2407-3-19 |
| Publisher version: | http://dx.doi.org/10.1186/1471-2407-3-19 |
| Language: | English |
| Additional information: | © 2003 Sharma et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
| Keywords: | Ascites, ASSAY, assessment, CA, cancer, Carcinoma, chemosensitivity, Chemotherapy, Cisplatin, clinical, Complete, confidence, cycle, disease, in vitro, In-vitro, INVITRO, LA, LEVEL, MARKER, Methods, November, outcome, ovarian, ovarian cancer, OVARIAN-CANCER, Partial, Patient, patients, PROGRESSION, Radiology, RATES, RECURRENT, RELAPSE, Reproducibility, Reproducibility of Results, Resistance, response, RESPONSES, Result, SAMPLE, SAMPLES, SERIES, SURVIVAL, TERM, therapy, treatment, Tumor, UK, WEIGHT |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/31201 |
Archive Staff Only
 |
View Item |
